CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Porters Five Forces analysis

3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in in geriatric population
3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer

3.5.2. Restraints

3.5.2.1. High preferences for minimally invasive surgical therapies

3.5.3. Opportunities

3.5.3.1. Large number of products in pipeline
3.5.3.2. Opportunities in emerging economies

3.5.4. Impact analyses

3.6. Clinical trials

CHAPTER 4: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Alpha Blockers

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. 5-Alpha Reductase Inhibitors

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Phosphodiesterase 5 Inhibitor

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Others

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY

5.1. Overview

5.1.1. Market size and forecast

5.2. Mono Drug Therapy

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Combination Drug Therapy

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America benign prostatic hyperplasia therapeutics market, by country

6.2.2.1. U.S.

6.2.2.1.1. Market size and forecast, by therapeutic class
6.2.2.1.2. Market size and forecast, by therapy

6.2.2.2. Canada

6.2.2.2.1. Market size and forecast, by therapeutic class
6.2.2.2.2. Market size and forecast, by therapy

6.2.2.3. Mexico

6.2.2.3.1. Market size and forecast, by therapeutic class
6.2.2.3.2. Market size and forecast, by therapy

6.2.3. North America market size and forecast, by therapeutic class
6.2.4. North America market size and forecast, by therapy

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Market size and forecast, by therapeutic class
6.3.2.1.2. Market size and forecast, by therapy

6.3.2.2. France

6.3.2.2.1. Market size and forecast, by therapeutic class
6.3.2.2.2. Market size and forecast, by therapy

6.3.2.3. UK

6.3.2.3.1. Market size and forecast, by therapeutic class
6.3.2.3.2. Market size and forecast, by therapy

6.3.2.4. Italy

6.3.2.4.1. Market size and forecast, by therapeutic class
6.3.2.4.2. Market size and forecast, by therapy

6.3.2.5. Spain

6.3.2.5.1. Market size and forecast, by therapeutic class
6.3.2.5.2. Market size and forecast, by therapy

6.3.3. Rest of Europe

6.3.3.1.1. Market size and forecast, by therapeutic class
6.3.3.1.2. Market size and forecast, by therapy

6.3.4. Europe market size and forecast, by therapeutic class
6.3.5. Europe market size and forecast, by therapy

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Market size and forecast, by therapeutic class
6.4.2.1.2. Market size and forecast, by therapy

6.4.2.2. China

6.4.2.2.1. Market size and forecast, by therapeutic class
6.4.2.2.2. Market size and forecast, by therapy

6.4.2.3. India

6.4.2.3.1. Market size and forecast, by therapeutic class
6.4.2.3.2. Market size and forecast, by therapy

6.4.2.4. Australia

6.4.2.4.1. Market size and forecast, by therapeutic class
6.4.2.4.2. Market size and forecast, by therapy

6.4.2.5. South Korea

6.4.2.5.1. Market size and forecast, by therapeutic class
6.4.2.5.2. Market size and forecast, by therapy

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Market size and forecast, by therapeutic class
6.4.2.6.2. Market size and forecast, by therapy

6.4.3. Asia-Pacific market size and forecast, by therapeutic class
6.4.4. Asia-Pacific market size and forecast, by therapy

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Market size and forecast, by therapeutic class
6.5.2.1.2. Market size and forecast, by therapy

6.5.2.2. Saudi Arabia

6.5.2.2.1. Market size and forecast, by therapeutic class
6.5.2.2.2. Market size and forecast, by therapy

6.5.2.3. South Africa

6.5.2.3.1. Market size and forecast, by therapeutic class
6.5.2.3.2. Market size and forecast, by therapy

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Market size and forecast, by therapeutic class
6.5.2.4.2. Market size and forecast, by therapy

6.5.3. LAMEA market size and forecast, by therapeutic class
6.5.4. LAMEA market size and forecast, by therapy

CHAPTER 7: COMPANY PROFILES

7.1. Abbott Laboratories

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance

7.2. Allergan plc

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance

7.3. Astellas Pharma Inc.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance

7.4. Boehringer Ingelheim Pharma GmbH & Co. KG

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance

7.5. Eli Lilly and Company

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance

7.6. GlaxoSmithKline plc.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance

7.7. Merck & Co., Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance

7.8. Pfizer Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance

7.9. Sanofi

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. Teva Pharmaceutical Industries Limited

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments